about
Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trialsOvercoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint BlockadeImmunostimulatory Gene Therapy Using Oncolytic Viruses as VehiclesViruses for tumor therapyPromising oncolytic agents for metastatic breast cancer treatmentTrial Watch: Immunomodulatory monoclonal antibodies for oncological indicationsOncolytic viral therapy for pancreatic cancer: current research and future directionsTrial Watch:: Oncolytic viruses for cancer therapyTrial Watch-Oncolytic viruses and cancer therapyTrial Watch-Immunostimulation with cytokines in cancer therapyPhase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myelomaHigh efficiency of alphaviral gene transfer in combination with 5-fluorouracil in a mouse mammary tumor model.Remission of disseminated cancer after systemic oncolytic virotherapyNovel immune checkpoint blocker approved for the treatment of advanced melanomaClassification of current anticancer immunotherapiesTargeted Hsp70 expression combined with CIK-activated immune reconstruction synergistically exerts antitumor efficacy in patient-derived hepatocellular carcinoma xenograft mouse models.Oncolytic Poxviruses.Tumor Selectivity of Oncolytic Parvoviruses: From in vitro and Animal Models to Cancer Patients.Combinatorial strategies for the induction of immunogenic cell death.The oncolytic effects of reovirus in canine solid tumor cell lines.Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective studyOncolytic measles virus efficacy in murine xenograft models of atypical teratoid rhabdoid tumorsA novel oHSV-1 targeting telomerase reverse transcriptase-positive cancer cells via tumor-specific promoters regulating the expression of ICP4Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death.Polymeric oncolytic adenovirus for cancer gene therapy.Oncolytic reovirus synergizes with chemotherapeutic agents to promote cell death in canine mammary gland tumorFirst oncolytic virus approved for melanoma immunotherapy.Chimeric antigen receptor-engineered T cells as oncolytic virus carriers.Assessment of current virotherapeutic application schemes: "hit hard and early" versus "killing softly"?Survivin promoter-regulated oncolytic adenovirus with Hsp70 gene exerts effective antitumor efficacy in gastric cancer immunotherapy.Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer.Evolving role of tumor antigens for future melanoma therapies.Changing faces in virology: the dutch shift from oncogenic to oncolytic viruses.The role of oncolytic virus immunotherapies to subvert cancer immune evasion.The oncolytic virus, pelareorep, as a novel anticancer agent: a review.Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?Arming oncolytic viruses to leverage antitumor immunity.Enhanced therapeutic effect using sequential administration of antigenically distinct oncolytic viruses expressing oncostatin M in a Syrian hamster orthotopic pancreatic cancer model.Oncolytic Immunotherapy for Treatment of Cancer.Targeting the hallmarks of cancer with therapy-induced endoplasmic reticulum (ER) stress.
P2860
Q26765115-2179F46B-C28D-4D1E-99CE-AED205365324Q26769977-361D5411-65BC-4266-B45E-42F6423F5D6CQ26777403-56525273-BEF3-4A3F-8EB6-0803A2106F81Q26823826-C50181EE-1D4E-42CA-8C87-02DD640D0A54Q26830620-BE42D885-ADF5-4473-88D2-31A12B05608DQ26996518-73C6B98B-DCF9-4209-84D0-A3DCDC5ECB8DQ27011439-4E60C8B0-BE02-4F66-83C6-452615195DA6Q27021951-D721195D-C9BF-4FAE-B44F-7D862C69F6ECQ28072347-2E98C541-8059-4E7B-87EF-87AD3CDD73ABQ28078725-01775C73-DC2A-4355-B2B3-6CA43EC591AFQ33441321-7061AD73-7E82-48A9-9447-47C6C6DA6694Q33828697-5CF62F32-52B6-4B8F-94C9-414099F1FF51Q34420326-8534A0ED-A66E-4895-9504-D7983246F033Q34936394-65D6349C-BE72-46DA-9BDF-9E4D476A142AQ35149637-945AA600-79F1-4E4C-8C14-E867EA6B75C0Q35176018-528BD226-3D2C-41E7-814B-C606C192B838Q35234349-13C6B82B-AD89-40D7-A7A4-A23D882F7896Q35522211-4839481D-93C6-4C76-A259-56C88FD2EF87Q35535140-AF2FEC57-1501-455F-A9A6-2B6C31EC7743Q35774578-241A15DD-892D-4532-B790-201665323A93Q36028552-1890C2A9-9974-46D6-8FF4-C2B41CED6F3AQ36250723-E850AE57-143E-49EA-89D3-8814189DF3BFQ36299683-E831E802-3D1E-4BBA-B84F-B506878B0324Q36301061-35BBE614-743F-4A7D-BD9D-5BDA27CE222DQ36344901-78355229-2721-4567-92E4-8AAA061C36C7Q36390114-FB9A16EF-A3AB-466D-A5E5-EBA1A09C3DC6Q36597333-116CE2E7-AEC1-4AED-8FAF-906617BCC2C1Q36664258-95234FE6-CC5B-4014-B19C-248F6AF767F1Q36664268-3D8CC943-6B0E-4CED-B873-8618A6991B88Q37649650-0112402C-9441-4388-B4AA-3073E62AB85BQ38223419-1377D9DD-4E19-4AFD-B919-82C2351410D0Q38232855-C660BFBE-884C-48F2-966B-B3B1F0D02485Q38241666-C663D8DC-0518-4190-B0F8-736B9AE199F9Q38357137-06B7D6AB-A3B0-4197-B396-7671537829E0Q38360781-6AD47947-9B87-4C22-87D0-8BC60E15E9CAQ38447992-ED9A4BCA-3D67-471C-BD48-5955ABBA1C38Q38470166-5E3354A4-962F-4E7D-9F64-361159C22E43Q38811582-217BD743-114C-4688-B809-7C8E92D34069Q38848223-74E869E9-9FF5-42F5-BF40-D45650664DA7Q38866745-798B9788-5BE4-4FA7-BA18-A7D6EB406961
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 April 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Trial watch: Oncolytic viruses for cancer therapy
@en
Trial watch: Oncolytic viruses for cancer therapy.
@nl
type
label
Trial watch: Oncolytic viruses for cancer therapy
@en
Trial watch: Oncolytic viruses for cancer therapy.
@nl
prefLabel
Trial watch: Oncolytic viruses for cancer therapy
@en
Trial watch: Oncolytic viruses for cancer therapy.
@nl
P2860
P50
P356
P1433
P1476
Trial watch: Oncolytic viruses for cancer therapy
@en
P2860
P304
P356
10.4161/ONCI.24612
P50
P577
2013-04-16T00:00:00Z